Are Max Healthcare Institute Ltd latest results good or bad?

3 hours ago
share
Share Via
Max Healthcare Institute Ltd's latest Q4 FY26 results show mixed performance, with a net profit increase of 13.72% sequentially and revenue growth of 3.65%. However, rising interest expenses, elevated debt, and high valuation metrics raise concerns about sustainability and future profitability.
Max Healthcare Institute Ltd's latest financial results for Q4 FY26 present a mixed operational picture. The company reported a net profit of ₹342.22 crores, reflecting a sequential growth of 13.72% from the previous quarter and a year-on-year increase of 7.28%. Revenue for the same quarter reached ₹2,142.89 crores, marking a 3.65% rise quarter-on-quarter and a 12.21% increase year-on-year. This revenue growth, although positive, indicates a deceleration compared to the company's historical five-year compound annual growth rate of 33.07%.
The operating margin for the quarter stood at 28.30%, which is the highest in recent periods, showing an improvement of 226 basis points sequentially. This suggests enhanced operational efficiency and better capacity utilization across the hospital network. However, the company is facing challenges with rising interest expenses, which reached ₹66.66 crores, representing a significant increase and reflecting an expanded debt profile. Despite the operational strengths, concerns have emerged regarding the company's elevated valuation metrics, as it trades at a price-to-earnings ratio of 73x, which is above the industry average. This premium valuation, coupled with a return on equity of 14.07% that remains below the sector average, raises questions about the sustainability of such valuations in light of the current growth rates. The company's financial structure shows a notable increase in long-term debt, which more than doubled from the previous fiscal year, leading to increased interest costs that could pressure future profitability. Additionally, the stock has underperformed compared to its sector peers, indicating a potential reassessment of its valuation by the market. Overall, the results indicate that while Max Healthcare has demonstrated operational strengths, there are significant headwinds related to rising costs and valuation concerns. The company saw an adjustment in its evaluation, reflecting these mixed operational trends and financial pressures.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News